AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8996151 — intervention group
Group type: EXPERIMENTAL
Intervention: ECF regimen (epirubicin, cisplatin, and protracted venous infusion fluorouracil)
Number of subjects: 274
Study 8996151 — intervention group
Group type: COMPARATOR
Intervention: FAMTX regimen (fluorouracil, doxorubicin, and methotrexate)
Number of subjects: 274
Study 8996151 — intervention group
Group type: EXPERIMENTAL
Intervention: ECF regimen
Number of subjects: 274
Study 8996151 — intervention group
Group type: COMPARATOR
Intervention: FAMTX regimen
Number of subjects: 274
Study 8430924 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 300 micrograms daily
Number of subjects: 22
Study 8430924 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 22
Study 3690961 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow section computed tomography
Number of subjects: 10
Study 3690961 — intervention group
Group type: COMPARATOR
Intervention: Plain chest radiography
Number of subjects: 10
Study 31997481 — intervention group
Group type: EXPERIMENTAL
Intervention: 25G atraumatic needle
Number of subjects: 952
Study 31997481 — intervention group
Group type: COMPARATOR
Intervention: Stylet reinsertion before needle withdrawal
Number of subjects: 952
Study 30982547 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI 160/14.4/10 μg
Number of subjects: 96
Study 30982547 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/14.4/10 μg
Number of subjects: 96
Study 30982547 — intervention group
Group type: COMPARATOR
Intervention: GFF MDI 14.4/10 μg
Number of subjects: 96
Study 28552090 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep NMB with 8 mmHg pneumoperitoneum
Number of subjects: 110
Study 28552090 — intervention group
Group type: COMPARATOR
Intervention: Standard NMB with 12 mmHg pneumoperitoneum
Number of subjects: 110
Study 26497730 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring intervention
Number of subjects: 30
Study 23088232 — intervention group
Group type: EXPERIMENTAL
Intervention: Role model interventions
Number of subjects: 0
Study 23088232 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐affirmation interventions
Number of subjects: 0
Study 21333879 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK without iris registration
Number of subjects: 3
Study 21333879 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK with static iris registration
Number of subjects: 3
Study 21333879 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK with dynamic iris registration
Number of subjects: 3
Study 17964295 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory therapy
Number of subjects: 19
Study 17964295 — intervention group
Group type: COMPARATOR
Intervention: Healthy children (control group)
Number of subjects: 19
Study 17040176 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive group therapy
Number of subjects: 72
Study 17040176 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretive group therapy
Number of subjects: 72
Study 12751039 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive oral ganciclovir therapy
Number of subjects: 29
Study 12751039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 10931518 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant therapy
Number of subjects: 0
Study 10931518 — intervention group
Group type: EXPERIMENTAL
Intervention: Cramer-von Mises statistic
Number of subjects: 0
Study 9056049 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal administered immediately after amlodipine
Number of subjects: 32
Study 9056049 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal administered 2 hours after amlodipine
Number of subjects: 32
Study 9056049 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal administered 6 hours after amlodipine
Number of subjects: 32
Study 9056049 — intervention group
Group type: COMPARATOR
Intervention: Control group (amlodipine ingested with 300 ml of water only)
Number of subjects: 32
Study 8877209 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-case adenoidectomy
Number of subjects: 429
Study 8877209 — intervention group
Group type: COMPARATOR
Intervention: Adenoidectomy (in combination with other minor procedures)
Number of subjects: 429
Study 29338322 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0
Study 29338322 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness (dispositional)
Number of subjects: 0
Study 29626287 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (group P)
Number of subjects: 50
Study 29626287 — intervention group
Group type: COMPARATOR
Intervention: Control group (group C)
Number of subjects: 50
Study 27227692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (cognitive behavioral therapy)
Number of subjects: 256
Study 27227692 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 256
Study 27227692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training
Number of subjects: 256
Study 24497963 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d added to interferon beta-1b (IFNB-1b)
Number of subjects: 77
Study 24497963 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1b (IFNB-1b) monotherapy
Number of subjects: 77
Study 21733267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass (FFM)
Number of subjects: 92
Study 21733267 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat mass (FM)
Number of subjects: 92
Study 21733267 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 92
Study 20974611 — intervention group
Group type: COMPARATOR
Intervention: Osmophobia prevalence in migraine patients (34.6%) vs tension-type headache patients (14.3%)
Number of subjects: 1020
Study 20974611 — intervention group
Group type: EXPERIMENTAL
Intervention: New diagnostic criteria for migraine without aura (MO) based on osmophobia
Number of subjects: 1020
Study 18677677 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive e‐Learning
Number of subjects: 104
Study 18677677 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual lecture (slides and audio)
Number of subjects: 104
Study 18677677 — intervention group
Group type: COMPARATOR
Intervention: Standard lecture (control group; 90 minutes)
Number of subjects: 104
Study 15997965 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional Care Series (PCS) toothbrush
Number of subjects: 61
Study 15997965 — intervention group
Group type: COMPARATOR
Intervention: Sonicare Elite (SE) toothbrush
Number of subjects: 61
Study 14991979 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclined body positioning (45 degrees orthostasis) during artificial pulmonary ventilation
Number of subjects: 0
Study 10489492 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate cream 0.1% applied once daily
Number of subjects: 60
Study 10489492 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate cream 0.05% applied twice daily
Number of subjects: 60
Study 9156881 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiographic assessment of pulmonary artery flow parameters in patients with COPD
Number of subjects: 50
Study 9156881 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without COPD)
Number of subjects: 50
Study 9156881 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler echocardiographic assessment of pulmonary artery flow parameters
Number of subjects: 50
Study 1874210 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate 1 mg kg‐1 followed by 1 mg kg‐1 h‐1
Number of subjects: 10
Study 1874210 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg kg‐1 followed by 9 mg kg‐1 h‐1
Number of subjects: 10
Study 10994430 — intervention group
Group type: EXPERIMENTAL
Intervention: Armstrong ventilator tube with paracentesis and fluid aspiration
Number of subjects: 0
Study 10994430 — intervention group
Group type: COMPARATOR
Intervention: Paracentesis and aspiration alone
Number of subjects: 0
Study 10994430 — intervention group
Group type: EXPERIMENTAL
Intervention: Armstrong tube
Number of subjects: 0
Study 30714249 — intervention group
Group type: EXPERIMENTAL
Intervention: Opium tincture (OT)
Number of subjects: 204
Study 30714249 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 204
Study 27881833 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 500
Study 27881833 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid
Number of subjects: 500
Study 27178570 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic group
Number of subjects: 63
Study 27178570 — intervention group
Group type: COMPARATOR
Intervention: Open group
Number of subjects: 63
Study 24914244 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin
Number of subjects: 16492
Study 24914244 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16492
Study 23241930 — intervention group
Group type: EXPERIMENTAL
Intervention: Meriva® (2 tablets/day, each containing 500 mg Meriva® corresponding to 100 mg curcumin) for at least 4 weeks
Number of subjects: 38
Study 23241930 — intervention group
Group type: COMPARATOR
Intervention: Standard management plan alone
Number of subjects: 38
Study 19185399 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Clinical Trials (RCTs)
Number of subjects: 0
Study 19185399 — intervention group
Group type: COMPARATOR
Intervention: Observational Studies
Number of subjects: 0
Study 17457375 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 53
Study 17457375 — intervention group
Group type: COMPARATOR
Intervention: Control (gentamicin without NAC)
Number of subjects: 53
Study 14998473 — intervention group
Group type: EXPERIMENTAL
Intervention: Easyhaler
Number of subjects: 30
Study 14998473 — intervention group
Group type: COMPARATOR
Intervention: Accuhaler
Number of subjects: 30
Study 14998473 — intervention group
Group type: COMPARATOR
Intervention: Turbuhaler
Number of subjects: 30
Study 11869770 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex sodium (DVPX) monotherapy, mean dose 882 mg qhs, mean level 80.7 mug/ml
Number of subjects: 19
Study 10437219 — intervention group
Group type: EXPERIMENTAL
Intervention: Qi Lü Tang Decoction for Improving Abnormal Heart Beat
Number of subjects: 84
Study 10437219 — intervention group
Group type: COMPARATOR
Intervention: Propafenone (Western drug)
Number of subjects: 84
Study 7850847 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% chlorhexidine (CHX) gel for 5 min/day for 9 days followed by 0.4% stannous fluoride (SnF2) gel for 14 days
Number of subjects: 19
Study 7850847 — intervention group
Group type: COMPARATOR
Intervention: 1% chlorhexidine (CHX) gel for 5 min/day for 9 days followed by placebo gel for 14 days
Number of subjects: 19
Study 3182439 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin (1 g bd for 10 days)
Number of subjects: 27
Study 3182439 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (200 mg on day 1, then 100 mg once a day from day 2 to day 10)
Number of subjects: 27
Study 30312595 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered graded exposure intervention added to manual therapy
Number of subjects: 49
Study 30312595 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 49
Study 30312595 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 28383927 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing (writing emotionally about traumatic life events)
Number of subjects: 76
Study 28383927 — intervention group
Group type: COMPARATOR
Intervention: Daily activities writing (writing objectively about daily activities)
Number of subjects: 76
Study 28383927 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 76
Study 26034248 — intervention group
Group type: EXPERIMENTAL
Intervention: DULCE intervention (family specialist support until 6-month visit)
Number of subjects: 330
Study 23497513 — intervention group
Group type: EXPERIMENTAL
Intervention: ICBT plus CBM (cognitive bias modification)
Number of subjects: 128
Study 23497513 — intervention group
Group type: COMPARATOR
Intervention: ICBT plus control training
Number of subjects: 128
Study 21190917 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Clarithromycin tablets 500 mg
Number of subjects: 14
Study 21190917 — intervention group
Group type: COMPARATOR
Intervention: Reference Clarithromycin tablets 500 mg
Number of subjects: 14
Study 18501094 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy/radiation
Number of subjects: 0
Study 18501094 — intervention group
Group type: EXPERIMENTAL
Intervention: Consolidation or maintenance therapy with targeted agents or conventional cytotoxic agents
Number of subjects: 0
Study 18501094 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation dose escalation using image-guided radiation therapy
Number of subjects: 0
Study 18501094 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer cytotoxic agents (e.g., pemetrexed)
Number of subjects: 0
Study 18501094 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted therapies (e.g., cetuximab, bevacizumab)
Number of subjects: 0
Study 16131513 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected men with lipoatrophy
Number of subjects: 6
Study 16131513 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 6
Study 14636091 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour of bilateral hand-arm vibration at 7.5 Hz and 0.38 cm displacement
Number of subjects: 14
Study 14636091 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 14
Study 11000588 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue Doppler Imaging (TDI) of the septal mitral annulus
Number of subjects: 36
Study 11000588 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without pseudonormalization)
Number of subjects: 36
Study 8848912 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram 0.5 mg.kg-1
Number of subjects: 40
Study 8848912 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram 0.5 mg.kg-1 with alfentanil pre-treatment
Number of subjects: 40
Study 8848912 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 40
Study 1537485 — intervention group
Group type: EXPERIMENTAL
Intervention: Active electrostimulation
Number of subjects: 50
Study 1537485 — intervention group
Group type: COMPARATOR
Intervention: Sham electrostimulation
Number of subjects: 50
Study 6376483 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 60
Study 6376483 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 60
Study 6376483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28953856 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (0, 1, or 2 mg/kg/day) from 6 weeks to 6 months of age
Number of subjects: 285
Study 28953856 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supplemented groups (1 or 2 mg/kg/day)
Number of subjects: 285
Study 28953856 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/kg/day)
Number of subjects: 285
Study 28953856 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (0, 1, or 2 mg/kg/day)
Number of subjects: 285
Study 27229464 — intervention group
Group type: EXPERIMENTAL
Intervention: SmokeFree Sports intervention
Number of subjects: 961
Study 27229464 — intervention group
Group type: COMPARATOR
Intervention: Control group (comparison schools)
Number of subjects: 961
Study 25595231 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical Test Theory (CTT)
Number of subjects: 240
Study 25595231 — intervention group
Group type: EXPERIMENTAL
Intervention: Item Response Theory (IRT)
Number of subjects: 240
Study 25595231 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasch Measurement Theory (RMT)
Number of subjects: 240
Study 23176547 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-week oral language intervention, delivered in three group sessions per week and daily sessions during transition to Reception class
Number of subjects: 180
Study 23176547 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 180
Study 23176547 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-week oral language intervention
Number of subjects: 180
Study 20471545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paclitaxel and cisplatin
Number of subjects: 0
Study 18626482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (environmental changes to promote physical activity)
Number of subjects: 954
Study 18626482 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 954
Study 16638440 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 percent CAAL
Number of subjects: 86
Study 16638440 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 percent CAAL
Number of subjects: 86
Study 16638440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 14529102 — intervention group
Group type: EXPERIMENTAL
Intervention: Roaring Adventures of Puff (RAP) education program
Number of subjects: 162
Study 14529102 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 162
Study 11127769 — intervention group
Group type: EXPERIMENTAL
Intervention: Kavosporal forte
Number of subjects: 20
Study 11127769 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 20
Study 9167741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cis-platinum (CDDP) 40 mg/m2 weekly with fractionated stereotactic radiotherapy (SRT) once or twice weekly
Number of subjects: 20
Study 9167741 — intervention group
Group type: COMPARATOR
Intervention: SRT
Number of subjects: 20
Study 8396083 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day once-daily for three days (n = 30)
Number of subjects: 60
Study 8396083 — intervention group
Group type: COMPARATOR
Intervention: Spiramycin 3,000,000 units three-times daily for seven days (n = 30)
Number of subjects: 60
Study 3543784 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior subTenon injections (subconjunctival)
Number of subjects: 77015
Study 3543784 — intervention group
Group type: COMPARATOR
Intervention: Posterior subTenon injections (retrobulbar)
Number of subjects: 77015
Study 30643806 — intervention group
Group type: EXPERIMENTAL
Intervention: Arsenic contaminated ground water exposure
Number of subjects: 960
Study 26342706 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark roasted coffee (DAR)
Number of subjects: 11
Study 26342706 — intervention group
Group type: EXPERIMENTAL
Intervention: Light roasted coffee (LIR)
Number of subjects: 11
Study 26342706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both coffees (LIR and DAR)
Number of subjects: 11
Study 26342706 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 11
Study 24885384 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flucloxacillin for 6 additional days after initial treatment
Number of subjects: 396
Study 24885384 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 additional days after initial treatment
Number of subjects: 396
Study 24885384 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral flucloxacillin for 6 additional days
Number of subjects: 396
Study 23279214 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic therapy program (3 days/week)
Number of subjects: 54
Study 23279214 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic therapy program (2 days/week)
Number of subjects: 54
Study 23279214 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 20223672 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide (100mg twice per day)
Number of subjects: 38
Study 20223672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 18484922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole
Number of subjects: 0
Study 18484922 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release formulation of ropinirole
Number of subjects: 0
Study 18484922 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16338507 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol nebulized in heliox
Number of subjects: 41
Study 16338507 — intervention group
Group type: COMPARATOR
Intervention: Control (standard therapy)
Number of subjects: 41
Study 14605041 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA)
Number of subjects: 20
Study 11000554 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine
Number of subjects: 4
Study 11000554 — intervention group
Group type: COMPARATOR
Intervention: Amberlite(R) IRP‐69
Number of subjects: 4
Study 11000554 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymer-coated cholestyramine
Number of subjects: 4
Study 11000554 — intervention group
Group type: COMPARATOR
Intervention: Polymer-coated IRP‐69
Number of subjects: 4
Study 8821521 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal tablets (Gynoflor) containing 50 mg of Lactobacillus acidophilus and 0.03 mg estriol, administered 1-2 tablets daily for 6 days.
Number of subjects: 32
Study 8821521 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 32
Study 8821521 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal tablets (Gynoflor)
Number of subjects: 32
Study 1384919 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (0.5 mg and then 1 mg twice daily for 4 days, then 2 mg twice daily for the remainder of the trial)
Number of subjects: 93
Study 1384919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 1384919 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 93
Study 1384919 — intervention group
Group type: COMPARATOR
Intervention: Prazosin and Placebo
Number of subjects: 93
Study 3929579 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-NTG 10 mg
Number of subjects: 15
Study 3929579 — intervention group
Group type: EXPERIMENTAL
Intervention: TTS-NTG 20 mg
Number of subjects: 15
Study 3929579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15